Skip to main navigation
Logo

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary May 15, 2013 Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
Ultragenyx Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
View HTML
PDF Version
Toggle Summary Jul 3, 2013 Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
View HTML
PDF Version
Toggle Summary Sep 3, 2013 Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
View HTML
PDF Version
Toggle Summary Jan 10, 2013 Ultragenyx Announces In-Licensing of Clinical-Stage Product Triheptanoin
Ultragenyx Announces In-Licensing of Clinical-Stage Product Triheptanoin
View HTML
PDF Version
Toggle Summary Aug 28, 2013 Ultragenyx Announces Presentation of Three Abstracts at the 12th International Congress of Inborn Errors of Metabolism (ICIEM 2013)
Ultragenyx Announces Presentation of Three Abstracts at the 12th International Congress of Inborn Errors of Metabolism (ICIEM 2013)
View HTML
PDF Version
Toggle Summary Oct 6, 2013 Ultragenyx Announces the Presentation of Data from a Single Dose Phase 1 Study, Conducted by Kyowa Hakko Kirin Co. Ltd. (KHK), of KRN23 in X-linked Hypophosphatemia (XLH) in Adults
Ultragenyx Announces the Presentation of Data from a Single Dose Phase 1 Study, Conducted by Kyowa Hakko Kirin Co. Ltd. (KHK), of KRN23 in X-linked Hypophosphatemia (XLH) in Adults
View HTML
PDF Version
Toggle Summary Sep 26, 2013 Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
View HTML
PDF Version
Toggle Summary Aug 5, 2013 Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
View HTML
PDF Version
Toggle Summary Dec 17, 2013 Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect
Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect
View HTML
PDF Version
Toggle Summary Aug 26, 2013 Ultragenyx Investigational New Drug Application for UX007 is Active
Ultragenyx Investigational New Drug Application for UX007 is Active
View HTML
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor FAQ
    • Contact Us

    Shareholder Tools

    • Email Alerts
    • Print
    • Share

  • Facebook
  • LinkedIn
  • Twitter
  • RSS
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
  • Medicines
    • Crysvita®
    • Mepsevii®
    • Dojolvi®
    • Dojolvi™ for Canada
    • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
  • Partnering
    • Current Partnerships
  • Contact
  • About
    • Management
      • Emil D. Kakkis, M.D., Ph.D.
      • Jayson Dallas, M.D.
      • Dennis Huang
      • Thomas Kassberg
      • Karah Parschauer
      • John Pinion
      • Shalini Sharp
    • Board of Directors
      • Daniel G. Welch
      • Emil D. Kakkis, M.D., Ph.D.
      • William Aliski
      • Deborah Dunsire, M.D.
      • Lars Ekman, M.D., Ph.D.
      • Matthew K. Fust
      • Michael Narachi
      • Clay B. Siegall, Ph.D.
    • Grants & Charitable Contributions
    • Our Commitment to Patients
    • Message from BIO
    • Medicines
      • Crysvita®
      • Mepsevii®
      • Dojolvi®
      • Dojolvi™ for Canada
      • DojolviMC–Français Canadien
  • Pipeline
    • DTX 301 for OTC
    • DTX 401 for GSDIa
  • For Patients
    • XLH
    • TIO
    • MPS 7
    • LC-FAOD
    • OTC
    • GSD1a
    • Access to Approved Therapies
    • Access to Investigational Therapies
  • Investors

      Investors

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • SEC Filings
      • Stock Information
      • Analyst Coverage
      • Investor FAQ
      • Contact Us
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Jobs
    Partnering
    • Current Partnerships
    Contact
    • Driving Directions
  • Privacy Policy
© 2021 Ultragenyx Pharmaceutical Inc.Website Design: Hane Chow, Inc.
  • Privacy Policy
  • Cookie Policy